Medical Doctor Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Archana Jayakumar

Pulmonary Disease San Francisco, CA Medical Doctor

NPI 1770742710 CMS profile 125452

2351 Clay St, Ste 501, San Francisco, CA 94115

Open in the dashboard

General payments

$1,028

5 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Archana Jayakumar of San Francisco, CA is reported in the CMS Open Payments database as having received $1,028 across 5 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 42nd percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $36 2
2023 General $993 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Archana Jayakumar
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Archana Jayakumar were reported at $36. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Archana Jayakumar Pulmonary Disease median Middle half National median
2019 $0 $377 $109–$1,340 $163
2020 $0 $230 $56–$907 $114
2021 $0 $269 $68–$1,072 $132
2022 $0 $390 $100–$1,457 $149
2023 $993 $419 $114–$1,659 $160
2024 $0 $476 $123–$1,818 $164
2025 $36 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Respicardia, Inc. $976 2 payments
  2. Lilly USA, LLC $36 2 payments
  3. Insmed, Inc. $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $674 4 payments
  2. Travel and Lodging $354 1 payment
Products named General payments · program years 2023–2025
  1. remede System $976 2 payments
  2. ZEPBOUND $36 2 payments
  3. MOUNJARO $17 1 payment
  4. Arikayce $16 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

327

Median for Pulmonary Disease: 936

Drug cost

$68,421

Median for Pulmonary Disease: $487,987

Branded share of claims

67.3%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 26 $23,673
Spiriva Respimat Tiotropium Bromide Brand 26 $22,686
Advair Hfa Fluticasone Propion/Salmeterol Brand 15 $8,960
Wixela Inhub Fluticasone Propion/Salmeterol Brand 21 $4,463
Breyna Budesonide/Formoterol Fumarate Brand 18 $2,752
Alvesco Ciclesonide Brand 13 $1,864
Albuterol Sulfate Hfa Albuterol Sulfate Brand 63 $1,543
Levalbuterol Tartrate Hfa Levalbuterol Tartrate Brand 16 $1,074
Prednisone Generic 70 $705
Fluticasone Propionate Generic 13 $229

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Records

5 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record